Latest On Syros Pharmaceuticals, Inc (SYRS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 10:55 EST | News | Syros Pharmaceuticals, Inc. (SYRS) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-10 07:36 EST | News | Syros Pharmaceuticals GAAP EPS of -$0.85 beats by $0.20, revenue of $3M misses by $0.3M | N/A | |
| 2023-04-06 19:30 EST | News | Syros Pharmaceuticals files for $250M mixed shelf offering - filing | N/A | |
| 2023-03-13 19:21 EST | News | RAPT Therapeutics, Repare Therapeutics among biotechs to disclose exposure to Silicon Valley Bank | N/A | |
| 2023-03-02 22:12 EST | News | Syros Pharmaceuticals GAAP EPS of -$0.17 beats by $1.13 | N/A | |
| 2023-03-02 22:12 EST | News | Syros Pharmaceuticals, Inc. (SYRS) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-01 16:52 EST | News | Syros Pharmaceuticals Q4 2022 Earnings Preview | N/A | |
| 2023-02-08 12:47 EST | News | Syros: Multiple Shots On Goal In Blood Cancer Space | N/A | |
| 2023-01-26 12:29 EST | News | Syros stock rises as tamibarotene gets FDA fast track status for rare blood cancer | N/A | |
| 2023-01-15 01:56 EST | News | Syros Pharmaceuticals A Buy Given Stock Price And Pipeline Potential (Rating Upgrade) | N/A | |
| 2022-11-14 15:38 EST | News | Syros Pharmaceuticals GAAP EPS of -$3.21 beats by $0.30, revenue of $3.9M misses by $1.28M | N/A | |
| 2022-11-14 15:37 EST | News | Syros Pharmaceuticals, Inc. (SYRS) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-11 17:30 EST | News | Syros Pharmaceuticals Q3 2022 Earnings Preview | N/A | |
| 2022-09-20 22:39 EST | News | Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders | N/A | |
| 2022-09-15 22:41 EST | News | Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger | N/A | |
| 2022-09-13 18:10 EST | News | Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609 | N/A | |
| 2022-08-10 06:03 EST | News | Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-10 06:03 EST | News | Syros Pharma stock slips after mixed Q2 results & a significant prior runup in shares | N/A | |
| 2022-08-09 08:23 EST | News | Syros Pharmaceuticals Q2 2022 Earnings Preview | N/A | |
| 2022-08-09 08:23 EST | News | Syros Pharmaceuticals GAAP EPS of -$0.54 misses by $0.13, revenue of $6.28M beats by $1.5M | N/A | |
| 2022-08-04 02:17 EST | News | Syros climbs 74% as EMA backs orphan drug designation for lead candidate | N/A | |
| 2022-05-16 19:40 EST | News | Syros Pharmaceuticals GAAP EPS of -$0.40 beats by $0.07, revenue of $5.47M beats by $0.55M | N/A | |
| 2022-05-16 19:39 EST | News | Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-14 03:57 EST | News | Syros Pharmaceuticals Q1 2022 Earnings Preview | N/A | |
| 2022-03-16 12:27 EST | News | Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-15 09:55 EST | News | Syros Pharmaceuticals GAAP EPS of -$0.38 beats by $0.08, revenue of $78M beats by $73.16M | N/A | |
| 2022-03-14 17:05 EST | News | Syros Pharmaceuticals Q4 2021 Earnings Preview | N/A | |
| 2022-02-03 01:25 EST | News | Syros rises 13% as tamibarotene gets FDA orphan drug status for myelodysplastic syndrome | N/A | |
| 2022-01-11 18:32 EST | News | Syros outlines clinical updates and 2022 goals | N/A | |
| 2021-11-19 20:21 EST | News | Syros Pharmaceuticals Is A Buy As New Trials Start | N/A | |
| 2021-11-05 13:55 EST | News | Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-04 16:56 EST | News | Syros Pharmaceuticals Q3 2021 Earnings Preview | N/A | |
| 2021-10-12 13:29 EST | News | Syros Pharmaceuticals names Jason Haas as CFO | N/A | |
| 2021-09-30 00:03 EST | News | Syros gets dosing underway in confirmation study of SY-2101 in acute promyelocytic leukemia | N/A | |
| 2021-09-28 02:29 EST | News | Syros Pharmaceuticals (SYRS) Investor Presentation | N/A | |
| 2021-09-22 07:31 EST | News | Syros Pharmaceuticals EPS beats by $0.03, beats on revenue | N/A | |
| 2021-09-22 07:08 EST | News | Syros Pharmaceuticals posts new data from early-stage SY-5609 cancer trial | N/A | |
| 2021-09-10 08:27 EST | News | Syros adds Deborah Dunsire to board of directors | N/A | |
| 2021-08-08 20:27 EST | News | Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-05 13:50 EST | News | Syros Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-07-22 02:59 EST | News | Syros Pharma up 18% day after ARK Innovation dumps shares | N/A | |
| 2021-07-22 02:36 EST | News | Syros: Pivotal Trial In MDS Ongoing | N/A | |
| 2021-05-06 19:44 EST | News | Syros Pharmaceuticals EPS beats by $0.24, beats on revenue | N/A | |
| 2021-03-23 10:37 EST | News | Revisiting Syros Pharmaceuticals | N/A | |
| 2021-03-08 12:35 EST | Analyst Rating | The Analyst Target Price has decreased from $17.14 to $16.57. | Neutral | |
| 2021-03-06 02:47 EST | News | Syros Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-03-06 00:52 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-05 12:27 EST | Earnings Estimate | An EPS average of -$1.72 is estimated for the 2022 year. | Sell | |
| 2021-03-05 12:27 EST | Earnings Estimate | An EPS average of -$0.38 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-05 05:48 EST | News | Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q4 2020 Results - Earnings Call Transcript | N/A | |
About Syros Pharmaceuticals, Inc (SYRS):
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
General
- Name Syros Pharmaceuticals, Inc
- Symbol SYRS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 103
- Fiscal Year EndDecember
- IPO Date2016-06-30
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.syros.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 27.25
- Price/Book (Most Recent Quarter) 6.08
- Enterprise Value Revenue 29.33
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.77
- Next Year EPS Estimate -$1.75
- Next Quarter EPS Estimate -$0.43
- Operating Margin -545%
- Return on Assets -28%
- Return on Equity -99%
- Revenue 15.09 million
- Earnings Per Share -$1.95
- Revenue Per Share $0.33
- Gross Profit 15.09 million
- Quarterly Earnings Growth 1021.9%
View More
Highlights
- Market Capitalization 561.53 million
- EBITDA -70088000
- PE Ratio -0.82
- Analyst Target Price $16.57
- Book Value Per Share $1.61
View More
Share Statistics
- Shares Outstanding 61.64 million
- Shares Float 56.72 million
- % Held by Insiders 1238%
- % Held by Institutions 101.58%
- Shares Short 4.03 million
- Shares Short Prior Month 3.64 million
- Short Ratio 6.63
- Short % of Float 10%
- Short % of Shares Outstanding 7%
View More
Technicals
- Beta 1.95
- 52 Week High $15.65
- 52 Week Low $4.88
- 50 Day Moving Average 10.18
- 200 Day Moving Average 9.92
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Syros Pharmaceuticals, Inc (SYRS) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Syros Pharmaceuticals, Inc (SYRS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-04 | $N/A | -$0.62 | -$0.51 | -20.55% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.43 | -$0.40 | -7.05% |
| 2020-06-30 | 2020-08-06 | $N/A | -$0.38 | -$0.42 | 9.52% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.39 | -$0.47 | 16.31% |
| 2019-12-31 | 2020-03-05 | $508000 | -$0.46 | -$0.48 | 4.96% |
| 2019-09-30 | 2019-11-12 | $558000 | -$0.47 | -$0.48 | 2.08% |
| 2019-06-30 | 2019-08-01 | $462000 | -$0.47 | -$0.41 | -14.63% |
| 2019-03-31 | 2019-05-01 | $454000 | -$0.49 | -$0.56 | 12.5% |
| 2018-12-31 | 2019-03-07 | $893000 | -$0.54 | -$0.49 | -9.31% |
| 2018-09-30 | 2018-11-01 | $412000 | -$0.47 | -$0.45 | -3.52% |
| 2018-06-30 | 2018-08-07 | $375000 | -$0.43 | -$0.50 | 13.43% |
| 2018-03-31 | 2018-05-10 | $370000 | -$0.48 | -$0.44 | -8.47% |
| 2017-12-31 | 2018-03-12 | $1.1 million | -$0.58 | -$0.57 | -1.31% |
| 2017-09-30 | 2017-11-08 | $N/A | -$0.53 | -$0.54 | 1.4% |
| 2017-06-30 | 2017-08-09 | $-1101000 | -$0.52 | -$0.59 | 11.37% |
| 2017-03-31 | 2017-05-15 | $1.1 million | -$0.49 | -$0.64 | 23.83% |
| 2016-12-31 | 2017-03-20 | $317000 | -$0.47 | -$0.64 | 26.1% |
| 2016-09-30 | 2016-11-14 | $N/A | -$0.65 | -$0.49 | -32.65% |
| 2016-06-30 | 2016-08-15 | $N/A | -$0.59 | -$0.53 | -12.76% |
Syros Pharmaceuticals, Inc (SYRS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 14.28 million |
| Income Before Tax | N/A | N/A | N/A | N/A | -19.73 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 6.4 million |
| Gross Profit | N/A | N/A | N/A | N/A | 508000 |
| Ebit | N/A | N/A | N/A | N/A | -20.17 million |
| Operating Income | N/A | N/A | N/A | N/A | -20.17 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | 508000 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 441000 |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | -19.73 million |
| Net Income Applicable to Common Shares | -30.13 million | -19.49 million | -17.2 million | -17.23 million | -19.73 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | 25 million | -54.57 million |
| Change to Liabilities | 829000 | -1.75 million | -1.96 million | 21.05 million | 1.09 million |
| Total Cash Flow from Investing Activities | -522000 | 4.01 million | 43.2 million | 16.95 million | -57.14 million |
| Net Borrowings | -61000 | -74000 | 19.66 million | -56000 | -55000 |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 1.09 million | -12000 |
| Change to Operating Activities | 534000 | 1.48 million | -2.28 million | 4.51 million | 4.65 million |
| Change in Cash | N/A | N/A | N/A | 7.44 million | -68.38 million |
| Total Cash from Operating Activities | -15.26 million | -12.43 million | 246000 | -10.6 million | -11.22 million |
| Depreciation | N/A | N/A | N/A | 898000 | 643000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | -20.16 million | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 2.72 million | 2.73 million | 2.41 million | 2.82 million | 2.19 million |
| Capital Expenditures | N/A | N/A | N/A | 8.16 million | 2.57 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 70.79 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 79.18 million |
| Other Current Liabilities | 12.21 million | 11.18 million | N/A | N/A | 5.74 million |
| Total Assets | N/A | N/A | N/A | N/A | 149.98 million |
| Common Stock | 56000 | 45000 | 45000 | 45000 | 43000 |
| Other Current Assets | N/A | N/A | N/A | N/A | 290000 |
| Retained Earnings | -377.02 million | -346.89 million | -327.41 million | -310.21 million | -292.98 million |
| Other Liabilities | 29.59 million | 14.22 million | 16.74 million | 20.68 million | 22.64 million |
| Other Assets | 5.05 million | 4.1 million | 4.13 million | 3.86 million | 3.58 million |
| Cash | N/A | N/A | N/A | N/A | 41.44 million |
| Total Current Liabilities | 28.62 million | 28.06 million | N/A | N/A | 23.52 million |
| Other Stockholder Equity | N/A | N/A | N/A | 3000 | 24000 |
| Property, Plant & Equipment | 29.64 million | 30.68 million | 31.24 million | 31.84 million | 31.89 million |
| Total Current Assets | 178.56 million | 98.56 million | N/A | N/A | 114.51 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 90.55 million | 45.94 million | 62.41 million | 76.54 million | 79.18 million |
| Short Term Investments | N/A | N/A | N/A | N/A | 49.98 million |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 3.6 million | 4.94 million | N/A | N/A | 5.85 million |
Syros Pharmaceuticals, Inc (SYRS) Chart:
Syros Pharmaceuticals, Inc (SYRS) News:
Below you will find a list of latest news for Syros Pharmaceuticals, Inc (SYRS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Syros Pharmaceuticals, Inc (SYRS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0 | CALL | 0 | 0 | 513.13 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0.41 | CALL | 0 | 94 | 123.56 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 10 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 12.5 | 0.05 | CALL | 0 | 5 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.65 | PUT | 0 | 100 | 141.07 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 188.5 | TRUE | 0 | 0 |
| 2024-05-17 | 10 | 0 | PUT | 0 | 0 | 264.65 | TRUE | 0 | 0 |
| 2024-05-17 | 12.5 | 0 | PUT | 0 | 0 | 398.49 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | CALL | 0 | 0 | 317.17 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 88.02 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 10 | 0 | CALL | 0 | 0 | 164.6 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 95.68 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 131.63 | TRUE | 0 | 0 |
| 2024-06-21 | 10 | 0 | PUT | 0 | 0 | 133.01 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 4.3 | CALL | 0 | 35 | 258.68 | TRUE | 0 | 0 |
| 2024-07-19 | 5 | 3 | CALL | 0 | 69 | 102.99 | TRUE | 0 | 0 |
| 2024-07-19 | 7.5 | 0.15 | CALL | 0 | 98 | 118.9 | FALSE | 0 | 0 |
| 2024-07-19 | 10 | 0.3 | CALL | 0 | 77 | 112.73 | FALSE | 0 | 0 |
| 2024-07-19 | 12.5 | 0 | CALL | 0 | 0 | 165.46 | FALSE | 0 | 0 |
| 2024-07-19 | 15 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 2.5 | 0.1 | PUT | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 0.6 | PUT | 0 | 20 | 106 | FALSE | 0 | 0 |
| 2024-07-19 | 7.5 | 3 | PUT | 0 | 0 | 115.58 | TRUE | 0 | 0 |
| 2024-07-19 | 10 | 0 | PUT | 0 | 0 | 120.8 | TRUE | 0 | 0 |
| 2024-07-19 | 12.5 | 0 | PUT | 0 | 0 | 137.47 | TRUE | 0 | 0 |
| 2024-07-19 | 15 | 0 | PUT | 0 | 0 | 166.49 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 3.68 | CALL | 0 | 502 | 128.27 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 2.35 | CALL | 0 | 20 | 103.77 | TRUE | 0 | 0 |
| 2024-10-18 | 7.5 | 0.55 | CALL | 0 | 27 | 108.8 | FALSE | 0 | 0 |
| 2024-10-18 | 10 | 0.25 | CALL | 0 | 23 | 120.87 | FALSE | 0 | 0 |
| 2024-10-18 | 12.5 | 0.5 | CALL | 0 | 50 | 106.87 | FALSE | 0 | 0 |
| 2024-10-18 | 15 | 0.4 | CALL | 0 | 23 | 127.12 | FALSE | 0 | 0 |
| 2024-10-18 | 2.5 | 0 | PUT | 0 | 0 | 121.38 | FALSE | 0 | 0 |
| 2024-10-18 | 5 | 1 | PUT | 0 | 1 | 102.65 | FALSE | 0 | 0 |
| 2024-10-18 | 7.5 | 0 | PUT | 0 | 0 | 106.88 | TRUE | 0 | 0 |
| 2024-10-18 | 10 | 0 | PUT | 0 | 0 | 113.07 | TRUE | 0 | 0 |
| 2024-10-18 | 12.5 | 0 | PUT | 0 | 0 | 119.89 | TRUE | 0 | 0 |
| 2024-10-18 | 15 | 0 | PUT | 0 | 0 | 135.48 | TRUE | 0 | 0 |
Latest SYRS Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:54 PM EST | 100 | $0.9506 |
| Jun 13, 2022 7:55 PM EST | 100 | $0.9524 |
| Jun 13, 2022 7:58 PM EST | 100 | $0.9525 |
| Jun 13, 2022 7:59 PM EST | 100 | $0.9549 |
| Jun 13, 2022 7:59 PM EST | 100 | $0.9547 |
Syros Pharmaceuticals, Inc (SYRS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000110465920076997/0001104659-20-076997-index.htm |
| 2018-08-15 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1556263/000000000018025231/0000000000-18-025231-index.htm |
| 2018-09-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1556263/000000000018028977/0000000000-18-028977-index.htm |
| 2020-06-17 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1556263/000000000020005409/0000000000-20-005409-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000021545719006653/0000215457-19-006653-index.htm |
| 2019-05-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000021545719007862/0000215457-19-007862-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000031506619001317/0000315066-19-001317-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000031506620001218/0000315066-20-001218-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000083423720008081/0000834237-20-008081-index.htm |
| 2020-04-02 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000089914020000230/0000899140-20-000230-index.htm |
| 2020-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000089924320005283/0000899243-20-005283-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000095010320002665/0000950103-20-002665-index.htm |
| 2019-03-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000225/0001012975-19-000225-index.htm |
| 2019-03-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000242/0001012975-19-000242-index.htm |
| 2019-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000489/0001012975-19-000489-index.htm |
| 2018-04-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1556263/000104746918003194/0001047469-18-003194-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000107261319000102/0001072613-19-000102-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000107261320000096/0001072613-20-000096-index.htm |
| 2018-03-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000110465918017641/0001104659-18-017641-index.htm |
| 2018-04-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1556263/000110465918026874/0001104659-18-026874-index.htm |
| 2018-06-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000110465918040331/0001104659-18-040331-index.htm |
| 2018-08-24 | 10-K/A | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1556263/000110465918053548/0001104659-18-053548-index.htm |
| 2018-08-24 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000110465918053549/0001104659-18-053549-index.htm |
| 2018-08-24 | 10-Q/A | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000110465918053550/0001104659-18-053550-index.htm |
| 2018-08-24 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1556263/000110465918053551/0001104659-18-053551-index.htm |
| 2018-09-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000110465918058596/0001104659-18-058596-index.htm |
| 2018-11-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000110465918068768/0001104659-18-068768-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000110465919000970/0001104659-19-000970-index.htm |
| 2019-01-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000110465919001621/0001104659-19-001621-index.htm |
| 2019-04-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000110465919020868/0001104659-19-020868-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000110465920021152/0001104659-20-021152-index.htm |
| 2020-06-25 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000110465920076997/0001104659-20-076997-index.htm |
| 2020-07-06 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000110465920081190/0001104659-20-081190-index.htm |
| 2020-08-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000110465920096870/0001104659-20-096870-index.htm |
| 2020-10-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000110465920113856/0001104659-20-113856-index.htm |
| 2019-09-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000114036119016285/0001140361-19-016285-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000114036120002960/0001140361-20-002960-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000114420419007784/0001144204-19-007784-index.htm |
| 2018-06-15 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000117911018008616/0001179110-18-008616-index.htm |
| 2018-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000117911018008617/0001179110-18-008617-index.htm |
| 2018-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000117911018008618/0001179110-18-008618-index.htm |
| 2018-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000117911018008619/0001179110-18-008619-index.htm |
| 2018-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000117911018008621/0001179110-18-008621-index.htm |
| 2018-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000117911018008622/0001179110-18-008622-index.htm |
| 2018-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000117911018008623/0001179110-18-008623-index.htm |
| 2018-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000117911018008624/0001179110-18-008624-index.htm |
| 2018-06-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000117911018008625/0001179110-18-008625-index.htm |
| 2018-12-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000117911018013361/0001179110-18-013361-index.htm |
| 2019-02-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1556263/000119312519039121/0001193125-19-039121-index.htm |
| 2019-03-07 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1556263/000119312519066569/0001193125-19-066569-index.htm |
| 2019-04-04 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1556263/000119312519097897/0001193125-19-097897-index.htm |
| 2019-04-04 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1556263/000119312519097903/0001193125-19-097903-index.htm |
| 2019-04-05 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1556263/000119312519098385/0001193125-19-098385-index.htm |
| 2019-04-05 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1556263/000119312519098389/0001193125-19-098389-index.htm |
| 2019-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312519099438/0001193125-19-099438-index.htm |
| 2019-04-08 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1556263/000119312519099440/0001193125-19-099440-index.htm |
| 2019-04-08 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1556263/000119312519099442/0001193125-19-099442-index.htm |
| 2019-04-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312519115861/0001193125-19-115861-index.htm |
| 2019-04-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1556263/000119312519118082/0001193125-19-118082-index.htm |
| 2019-04-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1556263/000119312519118086/0001193125-19-118086-index.htm |
| 2019-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312519171211/0001193125-19-171211-index.htm |
| 2019-10-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312519268940/0001193125-19-268940-index.htm |
| 2019-10-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312519273138/0001193125-19-273138-index.htm |
| 2019-10-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312519274743/0001193125-19-274743-index.htm |
| 2019-11-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312519283323/0001193125-19-283323-index.htm |
| 2019-12-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312519303728/0001193125-19-303728-index.htm |
| 2019-12-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312519316774/0001193125-19-316774-index.htm |
| 2019-12-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312519319786/0001193125-19-319786-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312520005784/0001193125-20-005784-index.htm |
| 2020-02-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312520034397/0001193125-20-034397-index.htm |
| 2020-03-05 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1556263/000119312520062209/0001193125-20-062209-index.htm |
| 2020-03-06 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1556263/000119312520065261/0001193125-20-065261-index.htm |
| 2020-04-28 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1556263/000119312520121908/0001193125-20-121908-index.htm |
| 2020-04-28 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1556263/000119312520121912/0001193125-20-121912-index.htm |
| 2020-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312520167170/0001193125-20-167170-index.htm |
| 2020-06-12 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1556263/000119312520167717/0001193125-20-167717-index.htm |
| 2020-06-18 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1556263/000119312520171851/0001193125-20-171851-index.htm |
| 2020-06-23 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1556263/000119312520176648/0001193125-20-176648-index.htm |
| 2020-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312520241676/0001193125-20-241676-index.htm |
| 2020-10-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000119312520275988/0001193125-20-275988-index.htm |
| 2019-04-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000119380519000352/0001193805-19-000352-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010282/0001209191-19-010282-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010283/0001209191-19-010283-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010284/0001209191-19-010284-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010285/0001209191-19-010285-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010287/0001209191-19-010287-index.htm |
| 2019-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010291/0001209191-19-010291-index.htm |
| 2019-06-12 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119036350/0001209191-19-036350-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119036355/0001209191-19-036355-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119036358/0001209191-19-036358-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119036359/0001209191-19-036359-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119036361/0001209191-19-036361-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119036364/0001209191-19-036364-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119036365/0001209191-19-036365-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119036366/0001209191-19-036366-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119036368/0001209191-19-036368-index.htm |
| 2019-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119036369/0001209191-19-036369-index.htm |
| 2019-08-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119046516/0001209191-19-046516-index.htm |
| 2019-11-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119056026/0001209191-19-056026-index.htm |
| 2019-12-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119061429/0001209191-19-061429-index.htm |
| 2019-12-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119061430/0001209191-19-061430-index.htm |
| 2019-12-23 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919119061818/0001209191-19-061818-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120009591/0001209191-20-009591-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120009593/0001209191-20-009593-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120009594/0001209191-20-009594-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120009595/0001209191-20-009595-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120009599/0001209191-20-009599-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120009600/0001209191-20-009600-index.htm |
| 2020-04-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120024775/0001209191-20-024775-index.htm |
| 2020-05-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120028871/0001209191-20-028871-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120029763/0001209191-20-029763-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120035964/0001209191-20-035964-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120035965/0001209191-20-035965-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120035966/0001209191-20-035966-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120035967/0001209191-20-035967-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120035968/0001209191-20-035968-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120035970/0001209191-20-035970-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120035971/0001209191-20-035971-index.htm |
| 2020-06-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120037001/0001209191-20-037001-index.htm |
| 2020-07-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120041574/0001209191-20-041574-index.htm |
| 2020-07-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120042796/0001209191-20-042796-index.htm |
| 2020-08-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120047501/0001209191-20-047501-index.htm |
| 2020-08-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120047504/0001209191-20-047504-index.htm |
| 2020-09-09 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120049802/0001209191-20-049802-index.htm |
| 2020-09-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120049803/0001209191-20-049803-index.htm |
| 2020-09-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120050618/0001209191-20-050618-index.htm |
| 2020-10-16 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120055059/0001209191-20-055059-index.htm |
| 2020-10-19 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1556263/000120919120055334/0001209191-20-055334-index.htm |
| 2019-09-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1556263/000121465919005720/0001214659-19-005720-index.htm |
| 2018-12-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1556263/000141057818000568/0001410578-18-000568-index.htm |
| 2018-05-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000155837018004563/0001558370-18-004563-index.htm |
| 2018-08-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000155837018006522/0001558370-18-006522-index.htm |
| 2018-11-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000155837018008210/0001558370-18-008210-index.htm |
| 2019-03-07 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1556263/000156459019006610/0001564590-19-006610-index.htm |
| 2019-05-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000156459019014558/0001564590-19-014558-index.htm |
| 2019-08-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000156459019027692/0001564590-19-027692-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000156459019042566/0001564590-19-042566-index.htm |
| 2020-03-05 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1556263/000156459020008795/0001564590-20-008795-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000156459020022351/0001564590-20-022351-index.htm |
| 2020-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000156459020037228/0001564590-20-037228-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1556263/000156459020051239/0001564590-20-051239-index.htm |
| 2020-06-22 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1556263/999999999520001499/9999999995-20-001499-index.htm |
| 2018-04-24 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1556263/999999999718005185/9999999997-18-005185-index.htm |
| 2018-11-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1556263/999999999718009025/9999999997-18-009025-index.htm |
| 2019-05-02 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1556263/999999999719003684/9999999997-19-003684-index.htm |
Syros Pharmaceuticals, Inc (SYRS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Syros Pharmaceuticals, Inc (SYRS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1238%Institutional Ownership: 10158%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-02-18 | Eric R Olson | Chief Scientific Officer | Sell | 1,446.00 | 7.38 | 10,674.08 | 0.00 | https://www.sec.gov/Archives/edgar/data/1556263/000089924320005283/0000899243-20-005283-index.htm |
| 2020-07-07 | Eric R Olson | Chief Scientific Officer | Sell | 1,753.00 | 11.72 | 20,538.50 | 0.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120041574/0001209191-20-041574-index.htm |
| 2020-08-17 | Eric R Olson | Chief Scientific Officer | Sell | 4,963.00 | 13.00 | 64,519.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120047504/0001209191-20-047504-index.htm |
| 2020-08-18 | Eric R Olson | Chief Scientific Officer | Sell | 10,787.00 | 13.00 | 140,231.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120047504/0001209191-20-047504-index.htm |
| 2020-05-13 | Mark J Alles | Director | Buy | 10,000.00 | 8.86 | 88,590.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120028871/0001209191-20-028871-index.htm |
| 2019-02-12 | Jeremy P. Springhorn | Chief Business Officer | Buy | 87,000.00 | 102,000.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010291/0001209191-19-010291-index.htm | ||
| 2020-08-18 | Eric R Olson | Chief Scientific Officer | Buy | 10,787.00 | 1.01 | 10,894.87 | 10,787.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120047504/0001209191-20-047504-index.htm |
| 2020-08-18 | SRINIVAS AKKARAJU | Director | Sell | 158,583.00 | 13.10 | 2,076,723.68 | 1,274,616.00 | https://www.sec.gov/Archives/edgar/data/1556263/000110465920096870/0001104659-20-096870-index.htm |
| 2020-08-17 | SRINIVAS AKKARAJU | Director | Sell | 744.00 | 13.00 | 9,672.00 | 1,433,199.00 | https://www.sec.gov/Archives/edgar/data/1556263/000110465920096870/0001104659-20-096870-index.htm |
| 2020-07-01 | SRINIVAS AKKARAJU | Director | Sell | 4,627.00 | 11.01 | 50,965.94 | 1,433,943.00 | https://www.sec.gov/Archives/edgar/data/1556263/000110465920081190/0001104659-20-081190-index.htm |
| 2020-06-25 | SRINIVAS AKKARAJU | Director | Sell | 54,972.00 | 11.15 | 612,849.84 | 1,438,570.00 | https://www.sec.gov/Archives/edgar/data/1556263/000110465920076997/0001104659-20-076997-index.htm |
| 2020-06-24 | SRINIVAS AKKARAJU | Director | Sell | 48,775.00 | 11.07 | 539,788.05 | 1,493,542.00 | https://www.sec.gov/Archives/edgar/data/1556263/000110465920076997/0001104659-20-076997-index.htm |
| 2020-06-23 | SRINIVAS AKKARAJU | Director | Sell | 50,953.00 | 11.11 | 565,929.88 | 1,542,317.00 | https://www.sec.gov/Archives/edgar/data/1556263/000110465920076997/0001104659-20-076997-index.htm |
| 2019-04-09 | SRINIVAS AKKARAJU | Director | Buy | 533,332.00 | 7.50 | 3,999,990.00 | 1,593,270.00 | https://www.sec.gov/Archives/edgar/data/1556263/000110465919020868/0001104659-19-020868-index.htm |
| 2019-11-11 | Jeremy P. Springhorn | Chief Business Officer | Buy | 9,879.00 | 4.99 | 49,327.82 | 24,879.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119056026/0001209191-19-056026-index.htm |
| 2020-10-19 | Richard A Young | Director | Sell | 5,673.00 | 8.75 | 49,638.75 | 335,201.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120055334/0001209191-20-055334-index.htm |
| 2020-10-15 | Richard A Young | Director | Sell | 317.00 | 8.75 | 2,773.75 | 340,874.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120055059/0001209191-20-055059-index.htm |
| 2020-09-15 | Richard A Young | Director | Sell | 5,990.00 | 10.39 | 62,236.10 | 341,191.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120050618/0001209191-20-050618-index.htm |
| 2020-08-17 | Richard A Young | Director | Sell | 5,990.00 | 12.59 | 75,414.10 | 347,181.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120047501/0001209191-20-047501-index.htm |
| 2019-11-12 | Jeremy P. Springhorn | Chief Business Officer | Buy | 10,121.00 | 4.97 | 50,267.97 | 35,000.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119056026/0001209191-19-056026-index.htm |
| 2020-07-15 | Richard A Young | Director | Sell | 5,990.00 | 11.85 | 70,981.50 | 353,171.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120042796/0001209191-20-042796-index.htm |
| 2020-06-15 | Richard A Young | Director | Sell | 5,990.00 | 8.75 | 52,412.50 | 359,161.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120037001/0001209191-20-037001-index.htm |
| 2020-05-15 | Richard A Young | Director | Sell | 5,990.00 | 9.22 | 55,242.18 | 365,151.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120029763/0001209191-20-029763-index.htm |
| 2020-04-15 | Richard A Young | Director | Sell | 23,960.00 | 8.75 | 209,650.00 | 371,141.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120024775/0001209191-20-024775-index.htm |
| 2019-08-16 | Richard A Young | Director | Sell | 22,700.00 | 10.00 | 227,000.00 | 395,101.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119046516/0001209191-19-046516-index.htm |
| 2019-08-15 | Richard A Young | Director | Sell | 2,300.00 | 10.00 | 23,000.00 | 417,801.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119046516/0001209191-19-046516-index.htm |
| 2019-07-17 | ARCH Venture Fund VII, L.P. | 10% Share Holder | Sell | 34,521.00 | 7.70 | 265,687.42 | 4,242,051.00 | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000489/0001012975-19-000489-index.htm |
| 2019-07-16 | ARCH Venture Fund VII, L.P. | 10% Share Holder | Sell | 25,779.00 | 7.81 | 201,277.28 | 4,276,572.00 | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000489/0001012975-19-000489-index.htm |
| 2019-07-15 | ARCH Venture Fund VII, L.P. | 10% Share Holder | Sell | 2,700.00 | 8.27 | 22,315.77 | 4,302,051.00 | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000489/0001012975-19-000489-index.htm |
| 2019-03-14 | ARCH Venture Fund VII, L.P. | 10% Share Holder | Sell | 43,000.00 | 8.15 | 350,441.40 | 4,305,051.00 | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000242/0001012975-19-000242-index.htm |
| 2019-03-13 | ARCH Venture Fund VII, L.P. | 10% Share Holder | Sell | 2,820.00 | 8.20 | 23,122.03 | 4,348,051.00 | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000242/0001012975-19-000242-index.htm |
| 2019-03-13 | ARCH Venture Fund VII, L.P. | 10% Share Holder | Sell | 81,591.00 | 7.89 | 643,442.94 | 4,350,871.00 | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000242/0001012975-19-000242-index.htm |
| 2019-03-12 | ARCH Venture Fund VII, L.P. | 10% Share Holder | Sell | 40,092.00 | 7.37 | 295,373.80 | 4,432,462.00 | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000242/0001012975-19-000242-index.htm |
| 2019-03-11 | ARCH Venture Fund VII, L.P. | 10% Share Holder | Sell | 44,878.00 | 6.49 | 291,365.93 | 4,472,554.00 | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000225/0001012975-19-000225-index.htm |
| 2019-03-08 | ARCH Venture Fund VII, L.P. | 10% Share Holder | Sell | 84,496.00 | 6.93 | 585,269.99 | 4,517,432.00 | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000225/0001012975-19-000225-index.htm |
| 2019-03-07 | ARCH Venture Fund VII, L.P. | 10% Share Holder | Sell | 35,209.00 | 6.87 | 242,012.58 | 4,601,928.00 | https://www.sec.gov/Archives/edgar/data/1556263/000101297519000225/0001012975-19-000225-index.htm |
| 2018-11-29 | Nancy A Simonian | President & CEO | Buy | 98,504.00 | 1.01 | 99,489.04 | 469,204.00 | https://www.sec.gov/Archives/edgar/data/1556263/000117911018013361/0001179110-18-013361-index.htm |
| 2018-11-29 | Nancy A Simonian | President & CEO | Buy | 12,084.00 | 3.04 | 36,735.36 | 481,288.00 | https://www.sec.gov/Archives/edgar/data/1556263/000117911018013361/0001179110-18-013361-index.htm |
| 2020-08-17 | Eric R Olson | Chief Scientific Officer | Buy | 4,963.00 | 1.01 | 5,012.63 | 4,963.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919120047504/0001209191-20-047504-index.htm |
| 2019-12-23 | Nancy A Simonian | President & CEO | Buy | 52,401.00 | 3.04 | 159,299.04 | 533,689.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119061818/0001209191-19-061818-index.htm |
| 2019-02-12 | Nancy A Simonian | President & CEO | Buy | 188,000.00 | 669,288.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010287/0001209191-19-010287-index.htm | ||
| 2019-02-12 | David Roth | Chief Medical Officer | Buy | 87,000.00 | 87,000.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010285/0001209191-19-010285-index.htm | ||
| 2019-02-12 | Eric R Olson | Chief Scientific Officer | Buy | 87,000.00 | 87,000.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010283/0001209191-19-010283-index.htm | ||
| 2019-02-12 | Gerald E Quirk | Chief Legal & Admin. Officer | Buy | 87,000.00 | 87,000.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010284/0001209191-19-010284-index.htm | ||
| 2019-02-12 | Joseph J Jr Ferra | Chief Financial Officer | Buy | 87,000.00 | 87,000.00 | https://www.sec.gov/Archives/edgar/data/1556263/000120919119010282/0001209191-19-010282-index.htm |